Neurozystizerkose

Zusammenfassung

Als eine der weltweit häufigsten Ursachen struktureller Epilepsien ist die Neurozystizerkose vor allem in Entwicklungsländern endemisch. Aufgrund von Migration und Fernreisen sind Neurozystizerkosen auch in Europa zunehmend häufiger zu finden. Die Symptome einer Neurozystizerkose können neben epileptischen Anfällen facettenreich sein und stellen eine differenzialdiagnostische Herausforderung dar. Die vorliegende Kasuistik schildert den Krankheitsverlauf eines Patienten, bei dem durch das Zusammenwirken aus Anamnese, Bildgebung und Serologie die Diagnose gesichert und eine spezifische Therapie eingeleitet werden konnte.

Abstract

Neurocysticercosis is a leading cause of acquired epilepsy worldwide and endemic in underdeveloped and developing regions. As a result of increased migration and traveling, cases of neurocysticercosis reach Europe more frequently. Neurological symptoms are multifarious and often nonspecific, so that neurocysticercosis poses a diagnostic challenge. We report a case of a patient in whom the diagnosis of neurocysticercosis was achieved quickly via the patient’s history, neuroimaging and serology.

Schlüsselwörter

Neurozystizerkose - strukturelle Epilepsie - Taenia solium

Key words

neurocysticercosis - epilepsy - Taenia solium

• Literatur

• 1 Sinha S, Shara BS. Neurocysticercosis: A review of current status and management. J Clin Neurosci 2009; 16: 867-876
• 2 Singh G, Burneo JG, Sander JW. From seizures to epilepsy and its substrates: Neurocysticercosis. Epilepsia 2013; 54: 783-792
• 3 Zammarchi L, Strohmeyer M, Bartalesi F et al. Epidemiology and Management of Cysticercosis and Taenia solium Taeniasis in Europe, Systematic Review 1190–2011. PLoS ONE 8
• 4 Fabiani S, Bruschi F. Neurocysticercosis in Europe: Still a public health concern not only for imported cases. Acta Trop 2013; 28: 18-26
• 5 Flisser A. Taeniasis and cysticercosis due to Taenia solium. Prog Clin Parasitol 1994; 4: 77-116
• 6 White Jr AC. Neurocysticercosis: update on epidemiology, pathogenesis, diagnosis and management. Ann Rev Med 2000; 51: 187-206
• 7 Nash TE, Del Brutto OH, Butman JA et al. Calcific neurocysticercosis and epileptogenesis. Neurol 2004; 62: 1934-1938
• 8 Garcia HH, Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4: 653-661
• 9 Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol 2014; 13: 1202-1215
• 10 Carpio A. Neurocysticercosis: an update. Lancet Infect Dis 2002; 2: 751-762
• 11 Del Brutto OH, Garcia HH. Chapter 25: Neurocysticercosis. Handbook Clin Neurol 2013; 114: 313-325
• 12 Carabin H, Ndimubanzi PC, Budke CM et al. Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis 2011; 5: e1152
• 13 Chawla S, Husain N, Kumar S et al. Correlative MR imaging and histopathology in porcine neurocysticerosis. J Magn Reson Imaging 2004; 20: 208-215
• 14 Lobato RD, Lamas E, Portillo JM et al. Hydrocephalus in cerebral cysticercosis. Pathogenic and therapeutic considerations. J Neurosurg 1981; 55: 786-793
• 15 Del Brutto OH, Roos KL, Coffey CS et al. Meta-analysis: Cystical drugs for neurocysticercosis: Albendazole and praziquantel. Ann Intern Med 2006; 145: 43-51
• 16 Garcia HH, Evans CAW, Nash TE et al. Current Consensus Guidelines for Treatment of Neurocysticercosis. Clin Microbiol Rev 2002; 15: 747-756
• 17 Naddaf E, Seeger SK, Strafstrom CE. Neurocysticercosis in Wisconsin: 3 cases and a review of the literature. WMJ 2014; 113: 74-78
• 18 Scheel CM, Khan A, Hancock K et al. Serodiagnosis of neurocysticercosis using synthetic 8-kD proteins: comparison of assay formats. Am J Trop Med Hyg 2005; 73: 771-776
• 19 Tsang VC, Brand JA, Boyer AE. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosis human cysticercosis (Taenia solium). J Infect Dis 1989; 159: 50-59
• 20 Rodriguez S, Dorny P, Tsang VC et al. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis 2009; 199: 1345-1352
• 21 Rodriquez S, Wilkins P, Dorny P. Immunological and molecular diagnosis of cysticercosis. Pathog Glob Health 2012; 106: 286-298
• 22 Arruda GC, Quagliato E, Rossi CL. Intrathecal synthesis of specific immunoglobulin G antibodies in neurocysticercosis: evaluation of antibody concentrations by enzyme-linked immunosorbent assay using a whole cysticercal extract and cyst vesicular fluid as antigens. Diagn Microbiol Infect Dis 2006; 54: 45-49
• 23 Garcia HH, Gonzales I, Lescano AG et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomized controlled trial. Lancet Inf Dis 2014; 14: 687-695
• 24 Venkatesan P. Albendazole. J Antimicrob Chemother 1998; 41: 145-147
• 25 Harnett W. The anthelmintic action of praziquantel. Parasitol Today 1988; 4: 144-146